<DOC>
	<DOCNO>NCT01968486</DOCNO>
	<brief_summary>To demonstrate efficacy ranibizumab combination reduced-fluence verteporfin photodynamic therapy ( RF-PDT ) patient subfoveal choroidal neovascularization secondary pathologic myopia ( PM ) .</brief_summary>
	<brief_title>Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab Choroidal Neovascularization Pathologic Myopia</brief_title>
	<detailed_description>Sixty patient receive ranibizumab 0.5 mg combine reduce fluence ( RF ) verteporfin PDT . Ranibizumab first administer patient follow seven day RF-PDT . Subsequently intravitreal ranibizumab ( IVR ) inject need ( pro nata ) . All patient evaluate every 4 week 48 week . Main Outcome Measures : Mean change best-corrected visual acuity ( BCVA ) baseline 48 week , reduce mean central foveal thickness ( CFT ) analyze optical coherence tomography ( OCT ) improve macular sensitivity register microperimetry ( MP ) evaluation .</detailed_description>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>pathologic myopia , define spherical equivalent great 6 D axial length 26 mm ( Carl Zeiss IOLMaster V 4.07 ; Carl Zeiss Meditec , Dublin , California , USA ) ; posterior pole myopic retinal change ( posterior staphyloma , chorioretinal atrophy , papillary crescent ) ; fluorescein angiography ( FA ) detection subfoveal juxtafoveal CNV ( CNV classify juxtafoveal lesion closer 200 mm geometric center foveal avascular zone ) ; clear ocular medium ; duration symptom longer 4 week enrollment . prior treatment CNV include previous intravitreal drug injection PDTV ; presence maculopathy diabetic retinopathy retinal vascular occlusion ; history recent myocardial infarction thromboembolic event ; ongoing uncontrolled hypertension glaucoma ; refractive medium opacity ; eye surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>